There is an increased incidence of malignancy in patients with dermatomyositis. It is unknown if the risk differs between the subtypes of dermatomyositis.
To (1) compare the prevalence of malignancy-associated dermatomyositis between patients with classic and clinically amyopathic disease and (2) determine factors associated with an increased risk of malignancy-associated disease.
Retrospective cohort study of 201 patients with adult-onset dermatomyositis prospectively enrolled in a longitudinal dermatomyositis database between July 2008 and April 2018 at an outpatient dermatology urban tertiary referral center. The main outcome measure was a diagnosis of malignancy, excluding nonmelanoma skin cancer.
There were 201 patients with adult-onset dermatomyositis: 142 (71%) classic and 59 (29%) clinically amyopathic. Within 2 years of diagnosis, the prevalences of malignancy-associated classic and clinically amyopathic dermatomyositis were 9.9% and 1.7%, respectively. In this time period, patients who were older at dermatomyositis diagnosis (P = .01) and had the classic subtype (P = .04) were significantly more likely to have an underlying malignancy on multivariable regression analysis.
This was a retrospective study of prospectively collected data at a single tertiary referral center.
Older age and classic dermatomyositis are independent risk factors for malignancy-associated dermatomyositis within 2 years of disease onset.Le texte complet de cet article est disponible en PDF.
Key words : connective tissue disease, dermatomyositis, malignancy, medical dermatology, paraneoplastic
Abbreviations used : ANA, CADM, CDM, CI, DM, ETDM, IRB, MA, MA-CADM, MA-CDM, MA-DM, NXP-2, OR
| Funding sources: Supported by the US Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development and Biomedical Laboratory Research and Development).
| Conflicts of interest: None disclosed.
| IRB approval status: Reviewed and approved by the University of Pennsylvania IRB (approval no. 829890).